Edition:
India

Axcella Health Inc (AXLA.OQ)

AXLA.OQ on NASDAQ Stock Exchange Global Market

6.77USD
1:30am IST
Change (% chg)

$0.01 (+0.15%)
Prev Close
$6.76
Open
$6.81
Day's High
$6.81
Day's Low
$6.60
Volume
1,978
Avg. Vol
--
52-wk High
$15.94
52-wk Low
$6.19

Summary

Name Age Since Current Position

William Hinshaw

President, Chief Executive Officer

Shane Maltbie

38 2019 Interim Principal Accounting Officer

Tony Tramontin

Senior Vice President of Research and Development , Chief Scientific Officer

Manu Chakravarthy

Senior Vice President of Clinical Development, Chief Medical Officer

Stephen Mitchener

Senior Vice President, chief Business Officer

Catherine Sohn

66 2019 Independent Director

Biographies

Name Description

William Hinshaw

Mr.Bill Hinshaw is President, Chief Executive Officer of Company.Bill Hinshaw brings 30 years of highly successful, geo-diverse experience in leading commercial, medical, clinical development, strategic, financial, legal, policy and operations teams for the life sciences industry.

Shane Maltbie

Mr. Shane Maltbie is Interim Principal Accounting Officer of the Company. Prior to joining the Company, he led the SEC reporting and technical accounting groups as the Director of Technical Accounting at PAREXEL International, a publicly traded clinical research organization. Prior to PAREXEL, Mr. Maltbie was a senior manager at Deloitte & Touche. Mr. Maltbie is a Certified Public Accountant in the Commonwealth of Massachusetts. He holds a Bachelor’s Degree in both Business Management and Accounting from Hartwick College and a Masters in Accountancy from Northeastern University.

Tony Tramontin

Mr.Tony Tramontin Ph.D. is Senior Vice President of Research and Development , Chief Scientific Officer of Company.Dr. Tramontin was a Partner in McKinsey & Company’s Global Healthcare Practice. Across a 13 year career, he advised biopharma executive teams on a wide variety of strategic, operational and organizational topics across the value chain. The majority of his work, however, focused specifically on research, medicine development and early aspects of commercialization. He co-founded and led McKinsey’s technical service line that helps biopharma executives with R&D project investment decisions, portfolio prioritization, risk management, therapeutic area strategy, and product launch strategy. Before joining McKinsey, Dr. Tramontin was an experimental neuroscientist conducting neural stem cell research at The Rockefeller University and in The University of California San Francisco Department of Neurosurgery. Dr. Tramontin holds a Ph.D. in Biology (neuroscience and endocrinology) from the University of Washington and a B.A. in Business from the University of Notre Dame.

Manu Chakravarthy

Mr.Manu V. Chakravarthy M.D., Ph.D. is Senior Vice President of Clinical Development, Chief Medical Officer of Company.Dr. Chakravarthy served as the Global Head of External R&D in diabetes and cardiovascular research at Eli Lilly & Co where he was responsible for external innovation efforts, including the identification/evaluation of novel therapeutics, platforms, and technologies for in/out-licensing, establishing academic collaborations, and consortia management across the value chain to complement and enhance Lilly’s internal R&D portfolio. He also served as the industry co-leader of the Innovative Medicine Initiative’s LITMUS project, one of the largest public-private consortia efforts to elucidate noninvasive biomarkers for NAFLD. Before his global leadership role at Lilly, Dr. Chakravarthy spent more than 7 years at Merck & Co., where he began his industry career in Experimental Medicine as an associate director and progressively gained increasing experience across the R&D spectrum from discovery, clinical pharmacology, biomarker development and late-stage drug development in endocrine, metabolic, neuroscience and anti-viral therapeutic areas. During this time, he assumed positions of increasing responsibility and leadership within the company, ultimately serving as a Distinguished Scientist and led the clinical pharmacology groups in Discovery Medicine for groups in diabetes and cardiometabolic diseases within Translational Medicine. Dr. Chakravarthy received his medical degree from the University of Texas Houston Medical School, his doctorate in cell biology & physiology from the University of Texas Graduate School of Biomedical Sciences and the MD Anderson Cancer Center, and his bachelor’s degree in Liberal Arts from St. John’s University. He completed a residency in Internal Medicine at the Hospital of the University of Pennsylvania and clinical Fellowship in Endocrinology, Diabetes & Metabolism at the Barnes-Jewish Hospital in St Louis.

Stephen Mitchener

Mr.Stephen Mitchener is Senior Vice President, chief Business Officer of Company.Dr. Mitchener built a 15-year career at Novartis Pharmaceuticals, most recently as Head of U.S. Oncology Strategy, Partnering and Operations. In this Executive team role, he led all business development and collaborations for Novartis U.S. Oncology across academic, big data, pipeline, product and technology partnering initiatives. In addition, he had responsibility for Loss of Exclusivity (LoE), Companion Diagnostic (CDx) and Enterprise Operations for a $5 billion P&L. Dr. Mitchener has also led both commercial evaluations for successful global product acquisitions and BD&L activities for multiple products. In his commercial roles, Dr. Mitchener helped lead and transition assets in immunology, infectious diseases, oncology and rare diseases from research through commercialization for the company. Previously, Dr. Mitchener was the Business Franchise Head at Novartis Oncology for Australia & New Zealand, managing 13 products including 5 new launches. Dr. Mitchener was a Board Observer for COTA Healthcare, where he provided guidance on operations, strategy, and Series C financing on behalf of Novartis Oncology. Dr. Mitchener received his Doctor of Pharmacy degree from the University of North Carolina at Chapel Hill and conducted his Postdoctoral work at Rutgers University and Novartis Oncology.

Catherine Sohn

Dr. Catherine Angell Sohn is Independent Director of the Company. Dr. Sohn held a series of leadership positions in strategic product and business development and commercial operating roles at GlaxoSmithKline plc and its predecessor companies, SmithKline Beecham and SK&F, most recently as Senior Vice President until 2010. She currently serves on the board of directors of Jazz Pharmaceuticals plc, a public commercial-stage biopharmaceutical company, Rubius Therapeutics, Inc., a public clinical-stage biopharmaceutical company and Landec Corporation, a public company with two divisions, a contract development and manufacturing organization and a natural food company. Dr. Sohn also is Chairman of BioEclipse Therapeutics, a private clinical stage biotechnology company. As an independent Director, Dr. Sohn has served as Chair of Nominating / Corporate Governance and Compensations Committees and as a member on Audit Committees. She previously served on the board of Neuralstem, Inc., a public biopharmaceutical company until 2017. Dr. Sohn received a Pharm.D. from the University of California, San Francisco, a certificate in professional development from the Wharton School at the University of Pennsylvania and is a NACD (National Association of Corporate Directors) Board Leadership Fellow.

Basic Compensation